Newfeed

Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in all t

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: